{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:41:19Z","timestamp":1694634079846},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11934-008-0052-x","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T06:57:52Z","timestamp":1224140272000},"page":"295-301","source":"Crossref","is-referenced-by-count":1,"title":["Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia"],"prefix":"10.1007","volume":"9","author":[{"given":"Hartmut","family":"Porst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Ulbrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,17]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/bmj.308.6934.929","volume":"308","author":"P. Abrams","year":"1994","unstructured":"Abrams P: New words for old: lower urinary tract symptoms for \u201cprostatism\u201d. BMJ 1994, 308:929\u2013930.","journal-title":"BMJ"},{"key":"52_CR2","first-page":"29","volume":"5","author":"C.G. Roehrborn","year":"2002","unstructured":"Roehrborn CG: Reducing the risk of benign prostatic hyperplasia progression. Rev Urol 2002, 5:29\u201338.","journal-title":"Rev Urol"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0094-0143(21)00662-5","volume":"22","author":"H.A. Guess","year":"1995","unstructured":"Guess HA: Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995, 22:247\u2013261.","journal-title":"Urol Clin North Am"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","volume":"361","author":"A. Thorpe","year":"2003","unstructured":"Thorpe A, Neal D: Benign prostatic hyperplasia. Lancet 2003, 361:1359\u20131367.","journal-title":"Lancet"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0022-5347(01)66254-2","volume":"155","author":"T.N. Chiricos","year":"1996","unstructured":"Chiricos TN, Sanford E: Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996, 155:1311\u20131316.","journal-title":"J Urol"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archfami.2.7.729","volume":"2","author":"S.J. Jacobsen","year":"1993","unstructured":"Jacobsen SJ, Guess HA, Panser L, et al.: A population-based study of health care-seeking behavior for treatment of urinary symptoms. Arch Fam Med 1993, 2:729\u2013735.","journal-title":"Arch Fam Med"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P. Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neururol Urodyn 2002, 21:167\u2013178.","journal-title":"Neururol Urodyn"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1464-410X.1975.tb03947.x","volume":"47","author":"M. Caine","year":"1975","unstructured":"Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Br J Urol 1975, 47:193\u2013202.","journal-title":"Br J Urol"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/jm00378a028","volume":"27","author":"G.H. Rasmusson","year":"1984","unstructured":"Rasmusson GH, Reynolds GF, Utre T, et al.: Azasteroids as inhibitors of rat 5-alpha reductase. J Med Chem 1984, 27:1690\u20131701.","journal-title":"J Med Chem"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000474256","volume":"24","author":"R.S. Kirby","year":"1993","unstructured":"Kirby RS, Vale J, Bryan J, et al.: Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. Eur Urol 1993, 24:20\u201326.","journal-title":"Eur Urol"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0090-4295(99)80291-X","volume":"46","author":"J.T. Andersen","year":"1995","unstructured":"Andersen, JT, Ekman P, Wolf H, et al.: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995, 46:631\u2013637.","journal-title":"Urology"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0149-2918(07)80077-4","volume":"29","author":"K.T. McVary","year":"2007","unstructured":"McVary KT: A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007, 29:387\u2013398.","journal-title":"Clin Ther"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pros.2990250204","volume":"25","author":"P. Drescher","year":"1994","unstructured":"Drescher P, Eckert RE, Madsen PO: Smooth muscle contractility in prostatic hyperplasia: rote of cyclic adenosine monophosphate. Prostate 1994, 25:76\u201380.","journal-title":"Prostate"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-1119(98)00303-5","volume":"216","author":"K. Loughney","year":"1998","unstructured":"Loughney K, Hill TR, Florio VA, et al.: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3\u2032,5\u2032-cyclic nucleotide phosphodiesterase. Gene 1998, 216:139\u2013147.","journal-title":"Gene"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1432-1327.1998.2550391.x","volume":"255","author":"N. Yanaka","year":"1998","unstructured":"Yanaka N, Kotera J, Ohtsuka A, et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998, 255:391\u2013393.","journal-title":"Eur J Biochem"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/bbrc.1998.8769","volume":"247","author":"P. Stacey","year":"1998","unstructured":"Stacey P, Rulten S, Dapling A, Phillips SC: Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998, 247:249\u2013254.","journal-title":"Biochem Biophys Res Commun"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/S0022-5347(05)65621-2","volume":"166","author":"S. Ueckert","year":"2001","unstructured":"Ueckert S, Kuethe A, Jonas U, et al.: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001, 166:2484\u20132490.","journal-title":"J Urol"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","volume":"49","author":"S. Ueckert","year":"2006","unstructured":"Ueckert S, Oelke M, Stief CG, et al.: Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006, 49:740\u2013745.","journal-title":"Eur Urol"},{"issue":"Suppl","key":"52_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(18)31753-1","volume":"177","author":"C.G. Stief","year":"2007","unstructured":"Stief CG, Porst H, Ulbrich E: Vardenafil in the treatment of symptomatic benign prostatic hyperplasia [abstract]. J Urol 2007, 177(Suppl):517.","journal-title":"J Urol"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","volume":"177","author":"K.T. McVary","year":"2007","unstructured":"McVary KT, Roehrborn CG, Kaminetsky JC, et al.: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401\u20131407.","journal-title":"J Urol"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","volume":"177","author":"K.T. McVary","year":"2007","unstructured":"McVary KT, Monnig W, Camps JL, et al.: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071\u20131077.","journal-title":"J Urol"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/mol.53.3.467","volume":"53","author":"J.H. Guh","year":"1998","unstructured":"Guh JH, Hwang TL, Ko FN, et al.: Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998, 53:467\u2013474.","journal-title":"Mol Pharmacol"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10077","volume":"51","author":"P.I. Adolfsson","year":"2002","unstructured":"Adolfsson PI, Ahlstrand C, Varenhorst E, et al.: Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 2002, 51:50\u201358.","journal-title":"Prostate"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0898-6568(03)00134-7","volume":"16","author":"A.L. Cook","year":"2004","unstructured":"Cook AL, Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 2004, 16:253\u2013261.","journal-title":"Cell Signal"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1464-410X.2006.06501.x","volume":"96","author":"H. Tinel","year":"2006","unstructured":"Tinel H, Stelte-Ludwig B, H\u00fcetter J, Sandor P: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006, 96:1259\u20131263.","journal-title":"BJU Int"},{"key":"52_CR26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0090-4295(99)80103-4","volume":"45","author":"M.C. Truss","year":"1995","unstructured":"Truss MC, Ueckert S, Stief CG, et al.: Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro. Urology 1995, 45:893\u2013901.","journal-title":"Urology"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00304074","volume":"24","author":"M.C. Truss","year":"1996","unstructured":"Truss MC, Ueckert S, Stief CG, et al.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Identification and characterization. Urol Res 1996, 24:123\u2013128.","journal-title":"Urol Res"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00304075","volume":"24","author":"M.C. Truss","year":"1996","unstructured":"Truss MC, Ueckert S, Stief CG, et al.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Effects of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996, 24:129\u2013134.","journal-title":"Urol Res"},{"key":"52_CR29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00240-001-0221-6","volume":"29","author":"Y. Qiu","year":"2001","unstructured":"Qiu Y, Kraft P, Craig EC, et al.: Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001, 29:388\u2013392.","journal-title":"Urol Res"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(01)01471-6","volume":"59","author":"Y. Qui","year":"2002","unstructured":"Qui Y, Kraft P, Craig EC, et al.: Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002, 59:145\u2013149.","journal-title":"Urology"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/en.2006-1079","volume":"148","author":"S. Filippi","year":"2007","unstructured":"Filippi S, Morelli AM, Sandner P, et al.: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148:1019\u20131029.","journal-title":"Endocrinology"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/01.ju.0000131609.96301.e6","volume":"172","author":"B. Gu","year":"2004","unstructured":"Gu B, Reiter JP, Schwinn DA, et al.: Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction. J Urol 2004, 172:758\u2013762.","journal-title":"J Urol"},{"key":"52_CR33","first-page":"357","volume":"290","author":"W. Conners","year":"2005","unstructured":"Conners W, Whitebeck C, Chicester P, et al.: L-NAME, a nitric oxide synthase inhibitor, diminishes oxidative damage in urinary bladder partial outlet obstruction. Am J Physiol 2005, 290:357\u2013363.","journal-title":"Am J Physiol"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0022-5347(18)31568-4","volume":"177","author":"S. Matsumoto","year":"2007","unstructured":"Matsumoto S, Watanabe E, Nakata Y, et al.: Bladder protective effects of PDE5 inhibition: efficacy of vardenafil on rat bladder with outlet obstruction. J Urol 2007, 177:446.","journal-title":"J Urol"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(18)30672-4","volume":"177","author":"C. Beamon","year":"2007","unstructured":"Beamon C, Salkini M, Mazur C, et al.: The effect of sildenafil citrate on bladder outlet obstruction in a mouse model. J Urol 2007, 177:140.","journal-title":"J Urol"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.juro.2007.07.048","volume":"178","author":"M. Gacci","year":"2007","unstructured":"Gacci M, Del Popolo G, Macchiarella A, et al.: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007, 178:2040\u20132043.","journal-title":"J Urol"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.eururo.2006.05.036","volume":"50","author":"H. Porst","year":"2006","unstructured":"Porst H, Sharlip ID, Hatzichristou D, et al.: Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 2006, 50:1086\u20131095.","journal-title":"Eur Urol"},{"key":"52_CR38","first-page":"27","volume":"50","author":"H. Porst","year":"2005","unstructured":"Porst H, Lungimayr G, Deutsch-\u00d6esterreichische STEADY-Studiengruppe: Efficacy and tolerability of vardenafil within the time window of 6 hours after administration and beyond. MMW-Fortschr Med Originalien 2005, 50:27\u201332.","journal-title":"MMW-Fortschr Med Originalien"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","volume":"169","author":"A. Athanasopoulos","year":"2003","unstructured":"Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253\u20132256.","journal-title":"J Urol"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"K.S. Lee","year":"2005","unstructured":"Lee KS, Choo MS, Kim DY, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334\u20131338.","journal-title":"J Urol"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","volume":"174","author":"S.A. Kaplan","year":"2005","unstructured":"Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273\u20132276.","journal-title":"J Urol"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","volume":"175","author":"P. Abrams","year":"2006","unstructured":"Abrams P, Kaplan SA, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999\u20131004.","journal-title":"J Urol"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1464-410X.1987.tb05033.x","volume":"60","author":"S.C. Harrison","year":"1987","unstructured":"Harrison SC, Hunnam GR, Farman P, et al.: Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 1987, 60:519\u2013522.","journal-title":"Br J Urol"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/01.ju.0000139986.08972.e3","volume":"172","author":"V. Mirone","year":"2004","unstructured":"Mirone V, Imbimbo C, Sessa G, et al.: Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 2004, 172:1386\u20131389.","journal-title":"J Urol"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.urology.2007.06.715","volume":"70","author":"S. Laschke","year":"2007","unstructured":"Laschke S, Carl S: Detrusor overactivity after prostate resection \u2014 preventing postoperative incontinence with darifenacin. 29th Congress Societ\u00e9 Internationale d\u2019 Urologie, Paris, France, September 2\u20136, 2007. Urology 2007, 70:254.","journal-title":"Urology"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1464-410X.2005.05456.x","volume":"95","author":"J. Nordling","year":"2005","unstructured":"Nordling J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005, 95:1006\u20131012.","journal-title":"BJU Int"},{"key":"52_CR47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","volume":"92","author":"C.G. Roehrborn","year":"2003","unstructured":"Roehrborn CG, Van Kerrebroeck P, Nordling J: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003, 92:257\u2013261.","journal-title":"BJU Int"},{"key":"52_CR48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1743-6109.2006.00274.x","volume":"3","author":"R.A. Costabile","year":"2006","unstructured":"Costabile RA, Steers WD: How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006, 3:676\u2013681.","journal-title":"J Sex Med"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2004.06.017","volume":"46","author":"S.C. Sak","year":"2004","unstructured":"Sak SC, Hussain C, Johnston C, et al.: What is the relationship between male sexual function and lower urinary tract symptoms (LUTS). Eur Urol 2004, 46:482\u2013487.","journal-title":"Eur Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-008-0052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-008-0052-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-008-0052-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T21:33:05Z","timestamp":1632000785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-008-0052-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11934-008-0052-x","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}